Back to top
more

DexCom (DXCM)

(Real Time Quote from BATS)

$135.64 USD

135.64
479,775

-2.23 (-1.62%)

Updated Apr 25, 2024 10:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Nalak Das headshot

Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.

Is It Worth Investing in DexCom (DXCM) Based on Wall Street's Bullish Views?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in DexCom (DXCM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Investment Ideas feature highlights: Tenet Healthcare and HCA Healthcare

by Zacks Equity Research

Tenet Healthcare and HCA Healthcare are part of the Zacks Investment Ideas article.

Bryan Hayes headshot

Medical Devices ETF Hits 52-Week High: Stocks to Watch

by Bryan Hayes

Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.

Roche (RHHBY) Launches AI-Based Predictive CGM Accu-Chek

by Zacks Equity Research

Roche (RHHBY) is likely to enter the growing diabetes market with its AI-enabled predictive glucose monitoring system that may revolutionize diabetes management.

DexCom (DXCM) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

The latest trading day saw DexCom (DXCM) settling at $133.04, representing a -1.63% change from its previous close.

Community Health (CYH), Cost Plus Drugs Unite to Lower Drug Cost

by Zacks Equity Research

Community Health (CYH) collaborates with Cost Plus Drug to reduce drug costs and shortages.

DexCom's (DXCM) Direct-to-Watch Feature to Boost Its G7 System

by Zacks Equity Research

DexCom (DXCM) announces its direct-to-Apple-Watch feature for the G7 CGM system, which is likely to help people in better management of diabetes monitoring.

DexCom (DXCM) Soars 10% This Week: What's Fueling the Gain?

by Zacks Equity Research

A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.

Are Medical Stocks Lagging DexCom (DXCM) This Year?

by Zacks Equity Research

Here is how DexCom (DXCM) and Ambrx Biopharma Inc. (AMAM) have performed compared to their sector so far this year.

Investors Heavily Search DexCom, Inc. (DXCM): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to DexCom (DXCM). This makes it worthwhile to examine what the stock has in store.

DexCom (DXCM) Soars 9.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

DexCom (DXCM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

DaVita (DVA) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about DaVita's (DVA) strength in its kidney care.

DaVita (DVA) Expands Operational Footprint Via New Agreement

by Zacks Equity Research

DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.

DexCom's (DXCM) Stelo Glucose Biosensor Receives FDA Approval

by Zacks Equity Research

DexCom's (DXCM) Stelo receives FDA clearance, which makes it the first FDA-approved glucose biosensor to be available over the counter.

DexCom (DXCM) Stock Moves -0.43%: What You Should Know

by Zacks Equity Research

DexCom (DXCM) closed at $121.78 in the latest trading session, marking a -0.43% move from the prior day.

DexCom (DXCM) Rises As Market Takes a Dip: Key Facts

by Zacks Equity Research

In the most recent trading session, DexCom (DXCM) closed at $122.30, indicating a +0.46% shift from the previous trading day.

Tenet Healthcare (THC) to Sell Hospitals to Refine Portfolio

by Zacks Equity Research

Tenet Healthcare (THC) enters an agreement with Adventist Health to divest two of THC's hospitals, and continue to make Conifer's revenue cycle management services available for the divested operations.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Is DexCom (DXCM) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in DexCom (DXCM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software

by Zacks Equity Research

ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio

by Zacks Equity Research

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Here is What to Know Beyond Why DexCom, Inc. (DXCM) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching DexCom (DXCM) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

DexCom (DXCM) Beats on Q4 Earnings, Strong CGM Demand Continues

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

DexCom (DXCM) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.